Skip to content
Medical Health Aged Care

Monash Expert: Senate report on assessment and support services for people with ADHD

Monash University 2 mins read

The Senate inquiry into assessment and support services for people with ADHD (attention deficit hyperactive disorder) has handed down its report.  

It found cost, location, cultural and gendered barriers to access and called for national consistency in diagnosis and treatment to improve the lives of those with the condition. 

Available to comment: 

Professor Mark Bellgrove, Deputy Head of School (Research), Monash University School of Psychological Sciences and Turner Institute for Brain and Mental Health; Director and Lead, Australian Evidence-Based Clinical Practice Guideline for ADHD, Australian ADHD Professionals Association (AADPA)
Contact details: +61, 0430 421 234 or mark.bellgrove@monash.edu  
Read more of Professor Belgrove’s commentary at Monash Lens 

  • What ADHD is
  • ADHD diagnosis
  • Latest treatment and guidelines
  • Barriers to effective treatment

The following can be attributed to Professor Bellgrove:

“The Senate Inquiry into Assessment and Support Services for People with ADHD is a landmark moment where the voices of both Australians with a lived experience and professionals involved in care, have been heard. The 15 recommendations are appropriate, practical and formulated with due consideration to both the evidence and the needs of consumers. 

“As a Director of the Australian ADHD Professionals Association (AADPA), and Lead for the development of Australia's ADHD Clinical Practice Guideline, I am delighted that our call for both a National Framework for ADHD (recommendation #1) and funding for the implementation of the ADHD Clinical Practice Guideline (recommendation #13) are put forward as recommendations for the Australian Government to consider. 

“I am also very pleased to see recommendations (#8) encouraging neurodiversity-affirming campaigns to actively shift social attitudes and reduce stigma.” 

Professor Bellgrove was the AADPA lead in the development of Australia's first NHMRC-approved Clinical Practice Guideline for ADHD and gave evidence at the Senate inquiry. The feasibility of implementation of the Guideline was listed within the terms of reference of the Senate inquiry and Recommendation 13 in the released report recommends that the Government consider investing in its implementation. 

For more Monash media stories visit our news & events site: monash.edu/news
For any other topics on which you may be seeking expert comment, contact the Monash University Media Unit on +61 3 9903 4840 or media@monash.edu

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.